The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy

International Journal of Cardiovascular Imaging

Volumn 30, Issue 2, 2014, Pages 431-438

  Paz, Yehuda Edo ^a   Bokhari, Sabahat ^a  

^a Department of Medicine   (United States)

Author keywords

Arrhythmia; Cardiac sarcoidosis; F18 fluorodeoxyglucose; Positron emission tomography

Indexed keywords

FLUORINE 18; NITROGEN 13;

ADULT; ARTICLE; ATRIOVENTRICULAR DISSOCIATION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CARDITIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERLIPIDEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LUNG ARTERY PRESSURE; LUNG SARCOIDOSIS; MALE; MIDDLE AGED; NONISCHEMIC CARDIOMYOPATHY; PET-CT SCANNER; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; SARCOIDOSIS; SINUS RHYTHM;

ADULT; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84898781623     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-013-0339-y     Document Type: Article

References (52)

1. Chung MK, Martin DO, Sprecher D et al (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104(24):2886-2891 (Pubitemid 33139098)
2. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT (2005) Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95(6):764-767 (Pubitemid 40340139)
3. Dernellis J, Panaretou M (2001) C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 56(6):375-380
4. Anderson JL, Allen Maycock CA, Lappe DL et al (2004) Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 94(10):1255-1259 (Pubitemid 39469943)
5. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ (2005) C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 98(1):73-77 (Pubitemid 40169856)
6. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A et al (2006) Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 97(5):659-661 (Pubitemid 43255035)
7. Sata N, Hamada N, Horinouchi T et al (2004) C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 45(3):441-445 (Pubitemid 41518887)
8. Aviles RJ, Martin DO, Apperson-Hansen C et al (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108(24):3006-3010 (Pubitemid 37553570)
9. Pena JM, MacFadyen J, Glynn RJ, Ridker PM (2012) High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 33(4):531-537
10. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H (2006) High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 108(3):346-353 (Pubitemid 43339801)
11. Wazni O, Martin DO, Marrouche NF et al (2005) C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 91(10):1303-1305 (Pubitemid 41360947)
12. Malouf JF, Kanagala R, Al Atawi FO et al (2005) High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 46(7):1284-1287 (Pubitemid 41615550)
13. Liu T, Li G, Li L, Korantzopoulos P (2007) Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 49(15):1642-1648 (Pubitemid 46551628)
14. Loricchio ML, Cianfrocca C, Pasceri V et al (2007) Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 99(10):1421-1424 (Pubitemid 46691310)
15. Blangy H, Sadoul N, Dousset B et al (2007) Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 9(9):724-729 (Pubitemid 47371644)
16. Wu KC, Gerstenblith G, Guallar E et al (2012) Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging 5(2):178-186
17. Smit MD, Maass AH, De Jong AM, Muller Kobold AC, Van Veldhuisen DJ, Van Gelder IC (2012) Role of inflammation in early atrial fibrillation recurrence. Europace 14(6):810-817
18. Rienstra M, Sun JX, Magnani JW et al (2012) White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol 109(4):533-537
19. Hu YF, Yeh HI, Tsao HM et al (2012) Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol 5(2):334-340
20. Okumura Y, Watanabe I, Nakai T et al (2011) Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 22(9):987-993
21. Hu YF, Yeh HI, Tsao HM et al (2011) Impact of circulating monocyte CD36 level on atrial fibrillation and subsequent catheter ablation. Heart Rhythm 8(5):650-656
22. Conway DS, Buggins P, Hughes E, Lip GY (2004) Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 148(3):462-466 (Pubitemid 39265119)
23. Matsuo T, Iwade K, Hirata N et al (2005) Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 20(1):8-12 (Pubitemid 40260300)
24. Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9):1071-1080 (Pubitemid 38541684)
25. Young-Xu Y, Jabbour S, Goldberg R et al (2003) Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92(12):1379-1383 (Pubitemid 37532555)
26. Siu CW, Lau CP, Tse HF (2003) Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92(11):1343-1345
27. Dentali F, Gianni M, Squizzato A et al (2011) Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost 106(2):363-370
28. Ozaydin M, Varol E, Aslan SM et al (2006) Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97(10):1490-1493
29. Vyas AK, Guo H, Moss AJ et al (2006) Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47(4):769-773 (Pubitemid 43243099)
30. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP (2003) Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42(1):81-87 (Pubitemid 36760765)
31. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G (2000) Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36(3):766-772
32. Kayikcioglu M, Can L, Evrengul H, Payzin S, Kultursay H (2003) The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 90(1):63-72 (Pubitemid 36734844)
33. Yared JP, Starr NJ, Torres FK et al (2000) Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg 69(5):1420-1424 (Pubitemid 30434869)
34. Halonen J, Halonen P, Jarvinen O et al (2007) Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 297(14):1562-1567 (Pubitemid 46588369)
35. Dernellis J, Panaretou M (2004) Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25(13):1100-1107 (Pubitemid 38842447)
36. Deftereos S, Giannopoulos G, Kossyvakis C et al (2012) Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 60(18):1790-1796
37. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A (1997) Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96(4):1180-1184 (Pubitemid 27344221)
38. Strain JE, Grose RM, Factor SM, Fisher JD (1983) Results of endomyocardial biopsy in patients with spontaneous ventricular tachycardia but without apparent structural heart disease. Circulation 68(6):1171-1181 (Pubitemid 14207028)
39. Sugrue DD, Holmes DR Jr, Gersh BJ et al (1984) Cardiac histologic findings in patients with life-threatening ventricular arrhythmias of unknown origin. J Am Coll Cardiol 4(5):952-957 (Pubitemid 15206644)
40. Silverman KJ, Hutchins GM, Bulkley BH (1978) Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58:1204-1211 (Pubitemid 9092005)
41. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y (1993) Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 43:372-376 (Pubitemid 23225816)
42. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H (1999) Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 138:299-302 (Pubitemid 29379681)
43. Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116(19):2216-2233 (Pubitemid 350060359)
44. Bar-Shalom R, Valdivia AY, Blaufox MD (2000) PET imaging in oncology. Semin Nucl Med 30(3):150-185 (Pubitemid 30469914)
45. Corstens FH, van der Meer JW (1999) Nuclear medicine's role in infection and inflammation. Lancet 354(9180):765-770 (Pubitemid 29405804)
46. Palmer WE, Rosenthal DI, Schoenberg OI et al (1995) Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 196(3):647-655
47. Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ (2004) Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 31(1):29-37 (Pubitemid 38133538)
48. Zhuang H, Yu JQ, Alavi A (2005) Applications of fluorodeoxy-glucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 43(1):121-134 (Pubitemid 40326564)
49. Rudd JH, Warburton EA, Fryer TD et al (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105(23):2708-2711 (Pubitemid 34615139)
50. Youssef G, Leung E, Mylonas I et al (2012) The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53(2):241-248
51. Chen S, Bokhari S (2011) Diagnosis of cardiac sarcoidosis through mismatched defects seen on N-13 NH3/F-18 FDG cardiac PET. Clin Nucl Med 36(12):1156-1157
52. Radulescu B, Imperiale A, Germain P, Ohlmann P (2010) Severe ventricular arrhythmias in a patient with cardiac sarcoidosis: insights from MRI and PET imaging and importance of early corticosteroid therapy. Eur Heart J 31(4):400